A comparison of treatment with 250 μg roflumilast versus 500 μg roflumilast versus placebo over 24 weeks in patients with chronic obstructive pulmonary disease (COPD)

Study identifier:BY217/M2-107

ClinicalTrials.gov identifier:N/A

EudraCT identifier:

CTIS identifier:N/A

Study Complete

Official Title

*Please Note* The Study you are attempting to view was acquired from Takeda by AstraZeneca and was disclosed initially by Takeda per their Transparency Policies. More information regarding this study may be available by contacting [email protected]

Medical condition

Chronic Obstructive Pulmonary Disease

Phase

Phase 3

Healthy volunteers

No

Study drug

-

Sex

All

Actual enrollment

1411

Study type

Interventional

Age

40 Years - Years

Date

Study Start Date: 01 Apr 2002
Primary Completion Date: -
Study Completion Date: 01 Jun 2003

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jun 2016 by Takeda

Sponsors

Takeda

Collaborators

-

Inclusion and exclusion criteria